Novel anti-HER2 ADCs vs dual anti-HER2 antibody for HER2-positive metastatic breast cancer failed to tyrosine kinase inhibitor
In HER2-positive MBC for whom TKI treatment has failed, novel anti-HER2 ADCs and the HP combined with chemotherapy regimen both showed moderate efficacy and tolerable toxicity. Novel anti-HER2 ADCs are the preferred treatment recommendation for TKI failure patients. Meanwhile, based on the results of this study, the HP combined with chemotherapy regimen may also be an option, especially for patients with low accessibility.
Authors
- Tao Wang (ORCID: https://orcid.org/0000-0002-2823-7937)
- Li Bian (ORCID: https://orcid.org/0000-0001-9916-3720)
- Song Wu (ORCID: https://orcid.org/0000-0002-8907-4545)
- Shaohua Zhang (ORCID: https://orcid.org/0000-0002-3911-2398)
- Feng Li (ORCID: https://orcid.org/0000-0002-0763-014X)
- Chenchen Ji (ORCID: https://orcid.org/0000-0002-6601-1285)
- Zefei Jiang
- Jianbin Li
Institutions
- Academy of Military Medical Sciences (CN)
- Chinese PLA General Hospital (CN)
- Beijing Institute of Power Machinery (China) (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-12-31
- DOI
- https://doi.org/10.1093/oncolo/oyae144
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.28